BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38382624)

  • 21. BHBA treatment improves cognitive function by targeting pleiotropic mechanisms in transgenic mouse model of Alzheimer's disease.
    Wu Y; Gong Y; Luan Y; Li Y; Liu J; Yue Z; Yuan B; Sun J; Xie C; Li L; Zhen J; Jin X; Zheng Y; Wang X; Xie L; Wang W
    FASEB J; 2020 Jan; 34(1):1412-1429. PubMed ID: 31914599
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Novel Apolipoprotein E Antagonist Functionally Blocks Apolipoprotein E Interaction With N-terminal Amyloid Precursor Protein, Reduces β-Amyloid-Associated Pathology, and Improves Cognition.
    Sawmiller D; Habib A; Hou H; Mori T; Fan A; Tian J; Zeng J; Giunta B; Sanberg PR; Mattson MP; Tan J
    Biol Psychiatry; 2019 Aug; 86(3):208-220. PubMed ID: 31208706
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The APMAP interactome reveals new modulators of APP processing and beta-amyloid production that are altered in Alzheimer's disease.
    Gerber H; Mosser S; Boury-Jamot B; Stumpe M; Piersigilli A; Goepfert C; Dengjel J; Albrecht U; Magara F; Fraering PC
    Acta Neuropathol Commun; 2019 Jan; 7(1):13. PubMed ID: 30704515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 14,15-Epoxyeicosatrienoic Acid Alleviates Pathology in a Mouse Model of Alzheimer's Disease.
    Chen W; Wang M; Zhu M; Xiong W; Qin X; Zhu X
    J Neurosci; 2020 Oct; 40(42):8188-8203. PubMed ID: 32973044
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CX3CR1 deficiency aggravates amyloid driven neuronal pathology and cognitive decline in Alzheimer's disease.
    Puntambekar SS; Moutinho M; Lin PB; Jadhav V; Tumbleson-Brink D; Balaji A; Benito MA; Xu G; Oblak A; Lasagna-Reeves CA; Landreth GE; Lamb BT
    Mol Neurodegener; 2022 Jun; 17(1):47. PubMed ID: 35764973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Theranostic F-SLOH mitigates Alzheimer's disease pathology involving TFEB and ameliorates cognitive functions in Alzheimer's disease models.
    Iyaswamy A; Wang X; Krishnamoorthi S; Kaliamoorthy V; Sreenivasmurthy SG; Kumar Durairajan SS; Song JX; Tong BC; Zhu Z; Su CF; Liu J; Cheung KH; Lu JH; Tan JQ; Li HW; Wong MS; Li M
    Redox Biol; 2022 May; 51():102280. PubMed ID: 35286997
    [TBL] [Abstract][Full Text] [Related]  

  • 27. LPS priming before plaque deposition impedes microglial activation and restrains Aβ pathology in the 5xFAD mouse model of Alzheimer's disease.
    Yang Y; García-Cruzado M; Zeng H; Camprubí-Ferrer L; Bahatyrevich-Kharitonik B; Bachiller S; Deierborg T
    Brain Behav Immun; 2023 Oct; 113():228-247. PubMed ID: 37437821
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abundance of Aβ₅-x like immunoreactivity in transgenic 5XFAD, APP/PS1KI and 3xTG mice, sporadic and familial Alzheimer's disease.
    Guzmán EA; Bouter Y; Richard BC; Lannfelt L; Ingelsson M; Paetau A; Verkkoniemi-Ahola A; Wirths O; Bayer TA
    Mol Neurodegener; 2014 Apr; 9():13. PubMed ID: 24694184
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Microglia prevent beta-amyloid plaque formation in the early stage of an Alzheimer's disease mouse model with suppression of glymphatic clearance.
    Feng W; Zhang Y; Wang Z; Xu H; Wu T; Marshall C; Gao J; Xiao M
    Alzheimers Res Ther; 2020 Oct; 12(1):125. PubMed ID: 33008458
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intraneuronal Aβ detection in 5xFAD mice by a new Aβ-specific antibody.
    Youmans KL; Tai LM; Kanekiyo T; Stine WB; Michon SC; Nwabuisi-Heath E; Manelli AM; Fu Y; Riordan S; Eimer WA; Binder L; Bu G; Yu C; Hartley DM; LaDu MJ
    Mol Neurodegener; 2012 Mar; 7():8. PubMed ID: 22423893
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Amyloid Precursor Protein is rapidly transported from the Golgi apparatus to the lysosome and where it is processed into beta-amyloid.
    Tam JH; Seah C; Pasternak SH
    Mol Brain; 2014 Aug; 7():54. PubMed ID: 25085554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased Alzheimer's disease-like pathology in the APP/ PS1ΔE9 mouse model lacking Nrf2 through modulation of autophagy.
    Joshi G; Gan KA; Johnson DA; Johnson JA
    Neurobiol Aging; 2015 Feb; 36(2):664-79. PubMed ID: 25316599
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Alzheimer disease: cellular and molecular aspects].
    Octave JN
    Bull Mem Acad R Med Belg; 2005; 160(10-12):445-9; discussion 450-1. PubMed ID: 16768248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metformin attenuates plaque-associated tau pathology and reduces amyloid-β burden in APP/PS1 mice.
    Chen Y; Zhao S; Fan Z; Li Z; Zhu Y; Shen T; Li K; Yan Y; Tian J; Liu Z; Zhang B
    Alzheimers Res Ther; 2021 Feb; 13(1):40. PubMed ID: 33563332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alzheimer's Disease is Driven by Intraneuronally Retained Beta-Amyloid Produced in the AD-Specific, βAPP-Independent Pathway: Current Perspective and Experimental Models for Tomorrow.
    Volloch V; Olsen B; Rits S
    Ann Integr Mol Med; 2020; 2(1):90-114. PubMed ID: 32617536
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Presenilin 1 regulates the processing of beta-amyloid precursor protein C-terminal fragments and the generation of amyloid beta-protein in endoplasmic reticulum and Golgi.
    Xia W; Zhang J; Ostaszewski BL; Kimberly WT; Seubert P; Koo EH; Shen J; Selkoe DJ
    Biochemistry; 1998 Nov; 37(47):16465-71. PubMed ID: 9843412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent Advances in the Modeling of Alzheimer's Disease.
    Sasaguri H; Hashimoto S; Watamura N; Sato K; Takamura R; Nagata K; Tsubuki S; Ohshima T; Yoshiki A; Sato K; Kumita W; Sasaki E; Kitazume S; Nilsson P; Winblad B; Saito T; Iwata N; Saido TC
    Front Neurosci; 2022; 16():807473. PubMed ID: 35431779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microglial mTOR Activation Upregulates Trem2 and Enhances β-Amyloid Plaque Clearance in the
    Shi Q; Chang C; Saliba A; Bhat MA
    J Neurosci; 2022 Jul; 42(27):5294-5313. PubMed ID: 35672148
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship between ubiquilin-1 and BACE1 in human Alzheimer's disease and APdE9 transgenic mouse brain and cell-based models.
    Natunen T; Takalo M; Kemppainen S; Leskelä S; Marttinen M; Kurkinen KMA; Pursiheimo JP; Sarajärvi T; Viswanathan J; Gabbouj S; Solje E; Tahvanainen E; Pirttimäki T; Kurki M; Paananen J; Rauramaa T; Miettinen P; Mäkinen P; Leinonen V; Soininen H; Airenne K; Tanzi RE; Tanila H; Haapasalo A; Hiltunen M
    Neurobiol Dis; 2016 Jan; 85():187-205. PubMed ID: 26563932
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intermittent hypoxia therapy ameliorates beta-amyloid pathology via TFEB-mediated autophagy in murine Alzheimer's disease.
    Wang X; Xie Y; Chen G; Lu Y; Wang D; Zhu L
    J Neuroinflammation; 2023 Oct; 20(1):240. PubMed ID: 37864249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.